Related Experiment Videos
[Inhalational antibiotic therapy in patients with cystic fibrosis and Pseudomonas infection]
C Mordasini1, C C Aebischer, O D Schoch
1Pneumologische Abteilung, Tiefenauspital Bern.
Abstract:
Treating chronic Pseudomonas infection of the bronchial tree is a very important part of the treatment strategy in patients with cystic fibrosis. There are only a few antibiotics which are effective against pseudomonas. Many of them soon lead to bacterial resistance (e.g. fluoro-quinolones). Inhaling antibiotics produces high sputum concentrations and low systemic toxicity. Tolerance is good and resistance rare. Several clinical studies, some of them doubleblind placebo controlled, have shown a positive effect of inhaled antibiotics on symptoms, on frequency of necessary i.v. therapies and also on pulmonary function. Most commonly aminoglycosides (tobramycin) and colistin, which is not yet registered in Switzerland, are used. The main indication is chronic therapy of Pseudomonas infection.
Insights
Inhaled antibiotics effectively treat chronic Pseudomonas infections in cystic fibrosis patients, improving symptoms and lung function while minimizing resistance and side effects. This approach offers a valuable therapeutic option for managing persistent bronchial infections.
Area of Science:
- Pulmonary Medicine
- Infectious Diseases
- Pharmacology
Context:
- Cystic fibrosis (CF) patients frequently suffer from chronic bronchial tree infections, primarily caused by Pseudomonas aeruginosa.
- Effective antibiotic treatment is crucial but challenged by limited drug options and the rapid development of bacterial resistance.
- Conventional antibiotic delivery often results in systemic toxicity and insufficient drug concentrations at the infection site.
Purpose:
- To evaluate the efficacy and safety of inhaled antibiotics as a treatment strategy for chronic Pseudomonas aeruginosa infections in cystic fibrosis.
- To assess the impact of inhaled antibiotic therapy on clinical symptoms, pulmonary function, and the need for intravenous treatments.
Summary:
- Inhaled antibiotics, such as aminoglycosides (e.g., tobramycin) and colistin, achieve high sputum concentrations with low systemic toxicity.
- Clinical studies, including double-blind, placebo-controlled trials, demonstrate positive outcomes for inhaled antibiotic therapy.
- Observed benefits include improved patient symptoms, reduced frequency of intravenous therapies, and enhanced pulmonary function.
Impact:
- Inhaled antibiotics represent a well-tolerated and effective therapeutic approach for managing chronic Pseudomonas infections in cystic fibrosis.
- This strategy helps mitigate the development of antibiotic resistance, a significant concern with other treatment modalities.
- The findings support the integration of inhaled antibiotics into the standard care guidelines for cystic fibrosis patients with chronic Pseudomonas aeruginosa colonization.